At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Not Yet Opened 08-10 16:00:00 EDT
8.57
+0.02
+0.23%
盘后8.64
+0.07+0.84%
19:59 EDT
High8.89Low8.41Vol2.15M
Open8.44D1 Closing8.55Amplitude5.67%
Mkt Cap693.32MTradable Cap547.85MTotal Shares80.90M
T/O18.43MT/O Rate3.36%Tradable Shares63.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Simply Wall St.  ·  08-01
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Phathom Pharmaceuticals is Maintained at Buy by Needham
Dow Jones  ·  07-31
Phathom Pharmaceuticals is Maintained at Buy by Needham
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
TIPRANKS  ·  07-31
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  07-31
Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025
Dow Jones  ·  07-31
Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025
Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth
Reuters  ·  07-30
Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth
Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million
Reuters  ·  07-30
Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million
Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate
Benzinga Earnings  ·  07-30
Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate
Phathom Pharmaceuticals Outlook FY Revenue USD 310-325 Million VS. Ibes Estimate USD 332.2 Million
THOMSON REUTERS  ·  07-30
Phathom Pharmaceuticals Outlook FY Revenue USD 310-325 Million VS. Ibes Estimate USD 332.2 Million
Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million
THOMSON REUTERS  ·  07-30
Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire  ·  07-30
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phathom Pharma Schedules Second-quarter Earnings Webcast
Reuters  ·  07-20
Phathom Pharma Schedules Second-quarter Earnings Webcast
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
GlobeNewswire  ·  07-20
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
TIPRANKS  ·  06-25
Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
TIPRANKS  ·  06-23
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
MT Newswires Live  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Reuters  ·  06-23
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
THOMSON REUTERS  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026
THOMSON REUTERS  ·  06-23
Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
GlobeNewswire  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--